Logo of global biopharmaceutical company Bristol-Myers Squibb is pictured on the blouse of an employee in Le Passage, near Agen, France March 29, 2018. REUTERS/Regis Duvignau
PHOTO: REGIS DUVIGNAU/REUTERS
Logo of global biopharmaceutical company Bristol-Myers Squibb is pictured on the blouse of an employee in Le Passage, near Agen, France March 29, 2018. REUTERS/Regis Duvignau
Now playing
03:16
Big pharma deal: Bristol-Myers Squibb to buy Celgene
Now playing
02:13
ECB president on women leaders: 'Of course we can do the job'
Now playing
01:36
Michael Bolton wants you to break up with Robinhood
Now playing
01:57
Fed chief downplays inflation concerns
Now playing
04:34
See what has happened to Trump's DC hotel after his loss
Now playing
01:41
Meet the 29-year-old cancer survivor set to make history in space
WASHINGTON, DC - JANUARY 15: MyPillow CEO Mike Lindell waits outside the West Wing of the White House before entering on January 15, 2021 in Washington, DC. (Photo by Drew Angerer/Getty Images)
PHOTO: Drew Angerer/Getty Images
WASHINGTON, DC - JANUARY 15: MyPillow CEO Mike Lindell waits outside the West Wing of the White House before entering on January 15, 2021 in Washington, DC. (Photo by Drew Angerer/Getty Images)
Now playing
00:39
MyPillow and its CEO Mike Lindell sued by Dominion
Bill Gates AC intv 022021
PHOTO: CNN
Bill Gates AC intv 022021
Now playing
02:32
Will Bill Gates go back to shaking hands? Hear his thoughts
02 Bill Gates AC intv 02202021
PHOTO: CNN
02 Bill Gates AC intv 02202021
Now playing
02:13
Bill Gates optimistic about climate policy under Biden WH
Now playing
05:37
Texas mayor: We were not prepared
Now playing
03:05
Watch lawmakers grill Robinhood's CEO
PHOTO: CNN
Now playing
04:47
ERCOT CEO explains how Texas power failure happened
NEW YORK, NEW YORK - OCTOBER 15: A person walks by a closed New York City business on October 15, 2020 in New York City. As American workers continue to struggle in an economy brought down by COVID-19, new jobless claims rose to 898,000 last week. It was the highest number since August 22 and represented a gain of 53,000 from the previous week
PHOTO: Spencer Platt/Getty Images
NEW YORK, NEW YORK - OCTOBER 15: A person walks by a closed New York City business on October 15, 2020 in New York City. As American workers continue to struggle in an economy brought down by COVID-19, new jobless claims rose to 898,000 last week. It was the highest number since August 22 and represented a gain of 53,000 from the previous week's upwardly revised total of 845,000. (Photo by Spencer Platt/Getty Images)
Now playing
01:11
Weekly initial jobless claims jump to 861,000
Now playing
02:42
A challenging year for women: Millions are out of work
MELBOURNE, AUSTRALIA - FEBRUARY 18: In this photo illustration a message is seen on Facebook mobile, on February 18, 2021 in Melbourne, Australia. Facebook has banned publishers and users in Australia from posting and sharing news content as the Australian government prepares to pass laws that will require social media companies to pay news publishers for sharing or using content on their platforms. (Photo by Robert Cianflone/Getty Images)
PHOTO: Robert Cianflone/Getty Images AsiaPac/Getty Images
MELBOURNE, AUSTRALIA - FEBRUARY 18: In this photo illustration a message is seen on Facebook mobile, on February 18, 2021 in Melbourne, Australia. Facebook has banned publishers and users in Australia from posting and sharing news content as the Australian government prepares to pass laws that will require social media companies to pay news publishers for sharing or using content on their platforms. (Photo by Robert Cianflone/Getty Images)
Now playing
03:05
Facebook blocks news sharing in Australia in response to government proposal
PHOTO: Anadolu Agency via Getty Images
Now playing
00:58
Watch Trump's Atlantic City casino implode
(CNN Business) —  

Drugmaker Bristol-Myers Squibb announced Thursday a $74 billion deal to buy Celgene, in one of the biggest mergers in pharmaceutical industry history.

The deal, which still needs the approval of shareholders and regulators, will be paid with a combination of stock and cash. Bristol-Myers is the result of a 1989 merger of two companies that traced their roots back to the 19th century, and is the eighth largest US drugmaker, with annual revenue of $20.8 billion in 2017. Celgene is the ninth largest with revenue of $13 billion.

The combined company could become the fourth largest pharmaceutical firm in the United States. Together they have nine different drugs - six from Bristol-Myers and three from Celgene - with global sales of more than $1 billion each, led by $8.2 billion in sales for Revlimid, the Celgene drug used to treat multiple myeloma, a cancer that affects bone marrow and white blood cells.

The companies also said they have six other drugs under development which could debut over the next 12 to 24 months, representing more than $15 billion in potential annual revenue. If three of its drugs receive FDA approval, Celgene shareholders will get an additional $9 for every current share of Celgene stock they held at the time of the merger, an unusual aspect to how the deal was structured.

But there are also concerns for both companies. Among them is the Trump administration promise to take action to reign in drug prices.

The companies also face looming patent expirations for Revlimid. That could bring generic competitors within four years. And Celgene’s purchase of Juno Therapeutics for $9 billion last year didn’t work out as planned. Shares of Celgene lost 39% during the course of 2018, making it ripe for a possible takeover.

Bristol-Myers has had its own problem as well, including the Food and Drug Administration pushing back a decision on its application for approval of two of its drugs , Opdivo and Yervoy. That delay sent shares tumbling 6% in October.

Shares of Bristol-Myers (BMY) tumbled more than 13% in Thursday’s trading session, while shares of Celgene (CELG) jumped 20%.